Additional Volume Molnupiravir (EIDD-2801/MK-4482) Supply Agreement for Pandemic Purposes

Official notice

Authority: Department of Health & Social Care (Central government)

GoodsAward procedure without prior publication of a call for competition

Sectors: Medical Devices & Pharma (33) Delivery: UK

Budget not disclosedValue not published

Awarded 20 Dec 2021no call for competition

Awarded to Merck Sharpe and Dohme (UK) Limited

What is being bought

Published requirement description

Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. <br/>This agreement is for the procurement of 1,750,000 units of Molnupiravir (EIDD-2801/MK-4482). It is one of the first oral and direct-acting antiviral drugs globally and the first to receive regulatory approval and is part of the UK’s multi-layered approach to COVID-19.

CPV: Pharmaceutical products

The lotProcurement structure

single lot · no lot value published

Lot #1Additional procurement of Molnupiravir (EIDD-2801/MK-4482)Awarded

Delivery: UK

Procedure terms & legal framework

From the official record · publisher note attached

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 17 Jan 2022, 18:15 GMT
Last source update: 17 Jan 2022, 18:15 GMT
FTS notice number: 2022/S 000-001380
Classification (CPV): Pharmaceutical products
Delivery area: UK
Official registry OCID: ocds-h6vhtk-030bfd Find a Tender

Why no open competition: Extreme urgency brought about by events unforeseeable for the contracting authority/entity and in accordance with the strict conditions stated in the directive
Published justification: Please see Contracts Finder Notice for full justification.

Publisher note: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors.

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast

Awards 1

Bids received 1

Contracts signed 1latest 20 Dec 2021

Awarded to	Value	Date	Status
Merck Sharpe and Dohme (UK) Limited	—	—	Awarded

Contracts

Contract 001380-2022-1 · Merck Sharpe and Dohme (UK) Limited
Signed
20 Dec 2021
Value
—
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	US$1 – US$1

Contracting authority & participating public bodies

Department of Health and Social Care

Contracting authorityCentral GovernmentMinistry or any other national or federal authority, including their regional or local subdivisionsHealth 39 Victoria Street, London, London, SW1H 0EUContact name, email

Dispute resolution & review bodies

The High CourtReview body LondonContact email

Bidders & participating suppliers

1 commercial party on the notice

Merck Sharpe and Dohme (UK) LimitedAwarded supplier00233687 120 Moorgate, London, London, EC2M 6UR

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.